Colorectal cancer (CRC) is the leading cause of cancer death; however, targets with broad anti-CRC effects are limited. Sirtuin6 (SIRT6) is a conserved nicotinamide adenine dinucleotide (NAD⁺)-dependent deacetylase that is widely pathologically downregulated in CRC.

MDL-811, an allosteric SIRT6 activator, enhances SIRT6 deacetylation.

Pharmacokinetic studies were performed by Medicilon, following standard protocols.

Reference:

Jialin Shang, et al. Small-molecule activating SIRT6 elicits therapeutic effects and synergistically promotes anti-tumor activity of vitamin D3 in colorectal cancer. Theranostics. 2020 Apr 27;10(13):5845-5864. doi: 10.7150/thno.44043. eCollection 2020.